Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Doevendans

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Antibodies (Basel, Switzerland)|September 24, 2019
Immunogenicity of Innovative and Biosimilar Monoclonal AntibodiesErik Doevendans, Huub Schellekens
Journal of Pharmaceutical Sciences|July 17, 2020
Protein Quality Testing in the Era of Personalized MedicineErik Doevendans, Huub Schellekens
Nature Biotechnology|December 16, 2024
The devolution of biosimilars regulationsErik Doevendans, Peter van Meer, Huub Schellekens
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 31, 2022
Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilarsAli M Alsamil, Thijs J Giezen, Toine C Egberts, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Antibodies (Basel, Switzerland)|September 24, 2019
Immunogenicity of Innovative and Biosimilar Monoclonal AntibodiesErik Doevendans, Huub Schellekens
Journal of Pharmaceutical Sciences|July 17, 2020
Protein Quality Testing in the Era of Personalized MedicineErik Doevendans, Huub Schellekens
Nature Biotechnology|December 16, 2024
The devolution of biosimilars regulationsErik Doevendans, Peter van Meer, Huub Schellekens
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 31, 2022
Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilarsAli M Alsamil, Thijs J Giezen, Toine C Egberts, et al.
Pageof 1